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t is generally believed that the onset of
type 2 diabetes can be insidious and
evade detection for prolonged time peri-
ods (1,2). Type 1 diabetes, however, often
displays a sudden clinical onset due to the
development of insufﬁcient insulin secre-
tory capacity following a pre-diabetic pe-
riod characterized by the presence of
pancreatic islet autoantibodies. Type 1 dia-
betes usually presents with symptoms, the
most frequent being polyuria and polydip-
sia (97%) and weight loss (46%) in one re-
cent study of newly diagnosed patients (3).
The article by Triolo et al. (4), in this
issue of Diabetes Care, addresses the pe-
riodinthedevelopmentoftype1diabetes
between the onset of hyperglycemia that
meets diagnostic criteria for diabetes and
its clinical presentation. Triolo et al.
present evidence that the onset of type 1
diabetes can occur without clinical symp-
toms and be difﬁcult to detect with the
current approach to diagnosis, which is
based on fasting plasma glucose (FPG)
measurement (5). These conclusions are
based on the results of semiannual oral
glucose tolerance tests for diabetes diag-
nosis among the Diabetes Prevention
Trial–Type 1 (DPT-1) participants. The
occurrenceofasymptomatictype1diabe-
tesintheDPT-1populationhasbeenpre-
viously reported (6). The important
additionalﬁndingsarethevalueofA1Cin
the detection of diabetes and the compar-
atively low occurrence of diabetic ketoac-
idosis (DKA) at diagnosis of diabetes. The
authors conclude by advising that “high-
riskrelativesmaybeneﬁtfromcloseatten-
tion or screening in order to prevent DKA
at diagnosis” (4).
The potential for screening to beneﬁt
high-risk subjects such as those included
in the DPT-1 requires further consider-
ation.Ofthe771subjectsincludedinthis
trial, 246 were diagnosed with diabetes
duringthecourseofthetrial;ofthese,167
were diagnosed by the OGTT, whereas
the remaining cases were diagnosed by
the FPG (n  29) or random plasma glu-
cose (n  42) testing that was, presum-
ably, performed because of a presence of
symptomsorelevatedhomeglucoseread-
ings. Only eight patients presented with
DKA. Not all subjects were asymptomatic
at the time of diagnosis. For the 218 sub-
jects with available data on presence of
symptoms, about one-third (36.7%) re-
ported the presence of at least one symp-
tom. If we assume that this proportion
applies to all 246 subjects diagnosed with
diabetes, then the number of individuals
needingtobescreenedwithasemiannual
OGTT in order to detect one asymptom-
aticcaseofdiabetesis771/(2460.633),
which is equal to ﬁve individuals. Al-
though this number is quite low, the real
beneﬁt from semiannual screening would
be the resulting decline in cases of DKA
that otherwise would have occurred had
screening not been in place. This number
can only be estimated by comparing the
DPT-1 experience with the literature, be-
cause there was no unscreened control
groupinthetrialthatwouldhaveallowed
for estimation of the incidence of DKA in
the absence of semiannual testing with
the OGTT. Assuming that 20–40% of
subjects who develop type 1 diabetes
presentwithDKA,andaccountingforthe
fact that 4% of new-onset cases in the
DPT-1 presented with this condition de-
spitesemiannualOGTTscreening,thein-
cidence of potentially preventable DKA
would range from 16–36% of cases (7).
Using this estimate to perform the above
equation for the number of individuals
screened with a semiannual OGTT
needed to detect one asymptomatic case
of diabetes leads to a range of 20 [771/
(246  0.16)] to 9 [771/(246  0.36)]
people. By these estimates, 9–20 high-
risk subjects would need to be screened
semiannually by OGTT to prevent one
case of DKA. These calculations probably
represent signiﬁcant underestimates, be-
cause it is highly likely that the DPT-1
participants have a greater level of diabe-
tes awareness that would most likely
translate into a lower risk of DKA, even in
the absence of screening. In addition,
other DPT-1 inclusion criteria may have
led to a risk of DKA that differs signiﬁ-
cantly from subjects who were ineligible
or declined participation. It has been
shown that clinical trial participants usu-
ally fare better than nonparticipants (8).
Conﬁrmation of the potential beneﬁt of
OGTTscreeninginautoantibody-positive
subjects at high risk for type 1 diabetes
would require a clinical trial to assess the
effects of screening on adverse outcomes.
Such a trial could be of further value by
assessing different frequencies of OGTT
screening (e.g., semiannual vs. annual).
It is discouraging, but not surprising,
that other measures of glycemia were not
deemed helpful in diagnosis. The 2-h
plasma glucose concentration generally
captures more cases of type 2 diabetes
than the FPG value in screening studies
for this outcome (9). The A1C reﬂects
nonenzymatic glycosylation of hemoglo-
bin in erythrocytes and requires time be-
fore an elevation in this level occurs, with
the midpoint between the starting level
and the new steady-state level requiring
30–35 days (10). One would expect that
the A1C would detect chronic hypergly-
cemia if it had been present for several
months. This ﬁnding is conﬁrmed by the
results of the DPT-1: 49% of subjects had
an A1C above the normal range of 6.2%.
In addition, the area under the A1C re-
ceiver operating characteristic curve of
0.86 in Fig. 1B of the original article
shows good ability to discriminate be-
tweenpatientswithandwithoutdiabetes.
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Editorials
EDITORIAL (SEE TRIOLO ET AL., P. 769)
966 DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009A different A1C cut point may deserve
further consideration as a marker for the
detection of diabetes in high-risk subjects
similar to those included in this study.
A high proportion of subjects diag-
nosed with diabetes had detectable C-
peptide levels, which would indicate a
potentially less complicated clinical
course with fewer microvascular compli-
cations and less severe hypoglycemia
based on results of the Diabetes Control
and Complications Trial, where higher
stimulated C-peptide levels were associ-
atedwithalesssevereclinicalcourse(11).
However, C-peptide concentration in the
DPT-1participantsmighthavecontinued
to fall despite earlier diagnosis, and it is
not clear that detectable C-peptide con-
centrationsweremorelikelytopersistasa
result of detection by OGTT screening.
On the other hand, if a future clinical trial
demonstrates that an intervention pre-
serves the relatively high level of C-
peptide found at diagnosis in the DPT-1,
this intervention would be expected to
have direct clinical beneﬁt.
The study by Triolo et al. shows that
periodic OGTT screening raises the po-
tential for a reduction in disease severity
at the time of type 1 diabetes onset. It is
certainly possible that this practice would
beacceptableanddesirabletoindividuals
at high risk for type 1 diabetes who are
extremelymotivatedandwillingtoaccept
the inconvenience of regular testing. As
the beneﬁt of this testing has not been
convincingly demonstrated, it cannot be
recommended as standard clinical prac-
tice.Also,thisreportshowsthattheonset
of type 1 diabetes may be asymptomatic
and undetectable by FPG measurement,
which runs counter to conventional wis-
dom. How much time it takes to progress
from asymptomatic to symptomatic type
1 diabetes is a major unanswered ques-
tion. Although not addressed by Triolo et
al., A1C may hold promise in identifying
the onset of type 1 diabetes, and further
diagnostic cut points should be examined
in this regard.
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